Stem Cell for Neurological Disorders
PARKINSON'S DISEASE NEED STEM CELL
MULTIPLE SCLEROSIS NEED STEM CELL
Benefits Stem Cells on Neurological Diseases and Neurodegenerative:
Parkinson's disease:
Studies have shown that mesenchymal stem cells can promote the regeneration of dopaminergic neurons, decrease inflammation and improve motor function in animal models of Parkinson's disease and in human clinical trials.
Cerebrovascular (stroke) sequelae:
Mesenchymal stem cells have shown beneficial effects on functional recovery after stroke by reducing inflammation, promoting neuronal regeneration and improving brain plasticity in preclinical models and clinical trials.
Multiple sclerosis (MS):
Mesenchymal stem cells have been shown to have immunomodulatory and anti-inflammatory properties that may reduce symptoms and progression of MS by modulating the immune response and promoting myelin regeneration.
Alzheimer's disease:
Although still in the research stages, it has been observed that mesenchymal stem cells may have neuroprotective and anti-inflammatory effects that could be beneficial in the treatment of Alzheimer's disease by improving cognitive function and reducing neuronal degeneration.
Amyotrophic lateral sclerosis (ALS):
Although more research is needed, preliminary studies suggest that mesenchymal stem cells may have neuroprotective effects and promote motor neuron survival in ALS patients, which could improve symptoms and slow disease progression.
Information of Neurological Disorders with Stem Cell
A blood sample from the patient is required at least 3 hours before the procedure to sensitize the MSC’s with the patient’s serum. Preferably take a blood sample 1 day before. When the patient is local and only has treatment with MSC’s, it may be easier to schedule the patient to come for sampling one day prior to their MSC’s treatment.
*Important; patients must pay in full 5 days prior to their scheduled treatment date to ensure fresh mesenchymal stem cells.
None of the patients have had any side effects as a result of the administration of mesenchymal stem cells.